Somech Raz, Shaklai Sigal, Geller Orit, Amariglio Ninette, Simon Amos J, Rechavi Gideon, Gal-Yam Einav Nili
Sheba Cancer Research Center and Institute of Hematology, The Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel.
J Cell Sci. 2005 Sep 1;118(Pt 17):4017-25. doi: 10.1242/jcs.02521.
Nuclear-envelope proteins have been implicated in diverse and fundamental cell functions, among them transcriptional regulation. Gene expression at the territory of the nuclear periphery is known to be repressed by epigenetic modifications such as histone deacetylation and methylation. However, the mechanism by which nuclear-envelope proteins are involved in such modifications is still obscure. We have previously shown that LAP2beta, an integral nuclear-envelope protein that contains the chromatin-binding LEM domain, was able to repress the transcriptional activity of the E2F5-DP3 heterodimer. Here, we show that LAP2beta's repressive activity is more general, encompassing various E2F members as well as other transcription factors such as p53 and NF-kappaB. We further show that LAP2beta interacts at the nuclear envelope with HDAC3, a class-I histone deacetylase, and that TSA (an HDAC inhibitor) abrogates LAP2beta's repressive activity. Finally, we show that LAP2beta is capable of inducing histone-H4 deacetylation. Our data provide evidence for the existence of a previously unknown repressive complex, composed of an integral nuclear membrane protein and a histone modifier, at the nuclear periphery.
核包膜蛋白参与多种重要的细胞功能,其中包括转录调控。已知核周区域的基因表达会受到组蛋白去乙酰化和甲基化等表观遗传修饰的抑制。然而,核包膜蛋白参与此类修饰的机制仍不清楚。我们之前已经表明,LAP2β是一种包含染色质结合LEM结构域的核包膜整合蛋白,它能够抑制E2F5-DP3异二聚体的转录活性。在这里,我们表明LAP2β的抑制活性更为普遍,涵盖各种E2F成员以及其他转录因子,如p53和NF-κB。我们进一步表明,LAP2β在核包膜处与I类组蛋白去乙酰化酶HDAC3相互作用,并且TSA(一种HDAC抑制剂)可消除LAP2β的抑制活性。最后,我们表明LAP2β能够诱导组蛋白H4去乙酰化。我们的数据为核周存在一种由核膜整合蛋白和组蛋白修饰剂组成的前所未知的抑制复合物提供了证据。